Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW Conjugate Vaccine in Toddlers
NCT02955797Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of meningococcal A conjugate vaccine in invasive meningococcal disease (IMD) (4 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Antibody Titers >= 1:8 Against Meningococcal Serogroups A, C, Y, and W at Day 30. Started Feb 2017; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
invasive meningococcal disease (IMD)
Beyond the preview
Go deeper on NCT02955797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955797.